PURPOSE: Screening multiple genes for inherited cancer predisposition expands opportunities for cancer prevention; however, reports of variants of uncertain significance (VUS) may limit clinical usefulness. We used an expert-driven approach, exploiting all available information, to evaluate multigene panels for inherited cancer predisposition in a clinical series that included multiple cancer types and complex family histories. METHODS: For 1,462 sequential patients referred for testing by BROCA or ColoSeq multigene panels, genomic DNA was sequenced and variants were interpreted by multiple experts using International Agency for Research on Cancer guidelines and incorporating evolutionary conservation, known and predicted variant consequences, and personal and family cancer history. Diagnostic yield was evaluated for various presenting conditions and family-history profiles. RESULTS: Of 1,462 patients, 12% carried damaging mutations in established cancer genes. Diagnostic yield varied by clinical presentation. Actionable results were identified for 13% of breast and colorectal cancer patients and for 4% of cancer-free subjects, based on their family histories of cancer. Incidental findings explaining cancer in neither the patient nor the family were present in 1.7% of subjects. Less than 1% of patients carried VUS in BRCA1 or BRCA2. For all genes combined, initial reports contained VUS for 10.5% of patients, which declined to 7.5% of patients after reclassification based on additional information. CONCLUSIONS: Individualized interpretation of gene panels is a complex medical activity. Interpretation by multiple experts in the context of personal and family histories maximizes actionable results and minimizes reports of VUS.Genet Med 18 10, 974-981.
PURPOSE: Screening multiple genes for inherited cancer predisposition expands opportunities for cancer prevention; however, reports of variants of uncertain significance (VUS) may limit clinical usefulness. We used an expert-driven approach, exploiting all available information, to evaluate multigene panels for inherited cancer predisposition in a clinical series that included multiple cancer types and complex family histories. METHODS: For 1,462 sequential patients referred for testing by BROCA or ColoSeq multigene panels, genomic DNA was sequenced and variants were interpreted by multiple experts using International Agency for Research on Cancer guidelines and incorporating evolutionary conservation, known and predicted variant consequences, and personal and family cancer history. Diagnostic yield was evaluated for various presenting conditions and family-history profiles. RESULTS: Of 1,462 patients, 12% carried damaging mutations in established cancer genes. Diagnostic yield varied by clinical presentation. Actionable results were identified for 13% of breast and colorectal cancer patients and for 4% of cancer-free subjects, based on their family histories of cancer. Incidental findings explaining cancer in neither the patient nor the family were present in 1.7% of subjects. Less than 1% of patients carried VUS in BRCA1 or BRCA2. For all genes combined, initial reports contained VUS for 10.5% of patients, which declined to 7.5% of patients after reclassification based on additional information. CONCLUSIONS: Individualized interpretation of gene panels is a complex medical activity. Interpretation by multiple experts in the context of personal and family histories maximizes actionable results and minimizes reports of VUS.Genet Med 18 10, 974-981.
Authors: Michael O Dorschner; Laura M Amendola; Emily H Turner; Peggy D Robertson; Brian H Shirts; Carlos J Gallego; Robin L Bennett; Kelly L Jones; Mari J Tokita; James T Bennett; Jerry H Kim; Elisabeth A Rosenthal; Daniel S Kim; Holly K Tabor; Michael J Bamshad; Arno G Motulsky; C Ronald Scott; Colin C Pritchard; Tom Walsh; Wylie Burke; Wendy H Raskind; Peter Byers; Fuki M Hisama; Deborah A Nickerson; Gail P Jarvik Journal: Am J Hum Genet Date: 2013-09-19 Impact factor: 11.025
Authors: Carlos J Gallego; Brian H Shirts; Caroline S Bennette; Greg Guzauskas; Laura M Amendola; Martha Horike-Pyne; Fuki M Hisama; Colin C Pritchard; William M Grady; Wylie Burke; Gail P Jarvik; David L Veenstra Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Yali Xue; Yuan Chen; Qasim Ayub; Ni Huang; Edward V Ball; Matthew Mort; Andrew D Phillips; Katy Shaw; Peter D Stenson; David N Cooper; Chris Tyler-Smith Journal: Am J Hum Genet Date: 2012-12-07 Impact factor: 11.025
Authors: Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian Journal: Hum Mutat Date: 2008-11 Impact factor: 4.878
Authors: Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: Hansook Kim Chong; Tao Wang; Hsiao-Mei Lu; Sara Seidler; Hong Lu; Steven Keiles; Elizabeth C Chao; A J Stuenkel; Xiang Li; Aaron M Elliott Journal: PLoS One Date: 2014-05-15 Impact factor: 3.240
Authors: Rachel Pearlman; Sigurdis Haraldsdottir; Albert de la Chapelle; Jon G Jonasson; Sandya Liyanarachchi; Wendy L Frankel; Thorunn Rafnar; Kari Stefansson; Colin C Pritchard; Heather Hampel Journal: J Med Genet Date: 2019-03-15 Impact factor: 6.318
Authors: Carolyn D Hurst; Olivia Alder; Fiona M Platt; Alastair Droop; Lucy F Stead; Julie E Burns; George J Burghel; Sunjay Jain; Leszek J Klimczak; Helen Lindsay; Jo-An Roulson; Claire F Taylor; Helene Thygesen; Angus J Cameron; Anne J Ridley; Helen R Mott; Dmitry A Gordenin; Margaret A Knowles Journal: Cancer Cell Date: 2017-11-13 Impact factor: 31.743
Authors: Silvia Casadei; Suleyman Gulsuner; Brian H Shirts; Jessica B Mandell; Hannah M Kortbawi; Barbara S Norquist; Elizabeth M Swisher; Ming K Lee; Yael Goldberg; Robert O'Connor; Zheng Tan; Colin C Pritchard; Mary-Claire King; Tom Walsh Journal: Proc Natl Acad Sci U S A Date: 2019-12-16 Impact factor: 11.205
Authors: Elisabeth A Rosenthal; Brian H Shirts; Laura M Amendola; Martha Horike-Pyne; Peggy D Robertson; Fuki M Hisama; Robin L Bennett; Michael O Dorschner; Deborah A Nickerson; Ian B Stanaway; Rami Nassir; Kathy T Vickers; Christopher Li; William M Grady; Ulrike Peters; Gail P Jarvik Journal: Hum Genet Date: 2018-09-28 Impact factor: 4.132
Authors: Y Nancy You; Ester Borras; Kyle Chang; Brandee A Price; Maureen Mork; George J Chang; Miguel A Rodriguez-Bigas; Brian K Bednarski; Funda Meric-Bernstam; Eduardo Vilar Journal: Dis Colon Rectum Date: 2019-04 Impact factor: 4.585
Authors: Tamara L Lotan; Harsimar B Kaur; Abdullah M Alharbi; Colin C Pritchard; Jonathan I Epstein Journal: Histopathology Date: 2019-04-01 Impact factor: 5.087